Zoom In IconArrows pointing outwardsNoom GLP-1 RXCourtesy of NoomDigital health company Noom on Thursday announced it will offer a compounded GLP-1 drug as part of a new weight loss product that starts at $149. The treatment will feature compounded semaglutide, the same active ingredient in Novo Nordisk's blockbuster obesity and diabetes drugs Wegovy and Ozempic.

放大Iconrowns指向外部NoomDigital health company Noom的GLP-1 RXCourtesy周四宣布，它将提供一种复合GLP-1药物，作为一种新减肥产品的一部分，起价149美元。该治疗将以复合semaglutide为特色，复合semaglutide与诺和诺德的重磅肥胖和糖尿病药物Wegovy和Ozempic中的相同活性成分。

Noom has offered weight loss programs for years, and consumers can already try to access those branded medications through its platform. But Noom is the latest in a string of digital health companies to offer compounded versions of the medications as a cheaper alternative for consumers while demand for weight loss and diabetes drugs spikes.

Noom多年来一直提供减肥计划，消费者已经可以尝试通过其平台获取这些品牌药物。但Noom是一系列数字健康公司中的最新一家，这些公司在减肥和糖尿病药物需求激增的同时，为消费者提供复合药物作为更便宜的替代品。

Hims & Hers and Sesame have launched similar programs in recent months — and the market for low-cost options has grown more competitive.  'Our position is that more supply, especially at a reasonable price, is needed right now, not less,' Noom CEO Geoff Cook told CNBC in an interview. Wegovy and Ozempic belong to a highly popular class of medications called GLP-1s, which mimic certain gut hormones to tamp down a patient's appetite and regulate their blood sugar.

Hims＆Hers和Sesame在最近几个月推出了类似的项目，低成本选项的市场竞争更加激烈。Noom首席执行官杰夫·库克（GeoffCook）在接受CNBC采访时表示，我们的立场是，现在需要更多的供应，尤其是以合理的价格供应。Wegovy和Ozempic属于一类非常受欢迎的药物，称为GLP-1s，它模仿某些肠道激素来抑制患者的食欲并调节血糖。

The compounded versions are custom-made alternatives to the brand drugs, and they can be produced when brand-name treatments are in shortage.Compounded GLP-1 medications are typically much cheaper than their branded counterparts. Wegovy and Ozempic both cost roughly $1,000 per month before insurance.

复合制剂是品牌药物的定制替代品，可以在品牌药物短缺时生产。复合GLP-1药物通常比品牌药物便宜得多。Wegovy和Ozempic在购买保险前每月都要花费大约1000美元。

Most insurance plans cover GLP-1s when they are used to treat diabetes, but coverage of the weight loss drugs is less widespread. Spiking demand can also make it difficult for many patients to find the branded treatments.Cook said consumers will pay $149 for their first month in Noom's program and $279 for the following .

当GLP-1用于治疗糖尿病时，大多数保险计划都涵盖了GLP-1，但减肥药物的覆盖范围较小。需求激增也会使许多患者难以找到品牌治疗。库克表示，消费者将在Noom计划的第一个月支付149美元，接下来支付279美元。